Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Continued Petitions

Diabetes (Continuous Glucose Monitoring Sensors) (PE1619)

Thursday 24 January 2019 Public Petitions Committee About 09:15–09:45 Petitions 68 contributions · 10 speakers

Speakers

Choose an MSP to read only their contributions

The record

68 contributions
Johann Lamont Lab The Convener · Glasgow
link

The first petition is PE1619, by Stuart Knox, on access to glucose monitoring. The petition calls for glucose monitoring sensors to be made available under prescription to all patients with type 1 diabetes. When the petition was last considered, which was in June 2018, issues were raised relating to the SIGN—Scottish intercollegiate guidelines network—guidelines for type 1 diabetes management and the VAT element of Scottish Government funding for additional insulin pumps as well as continuous glucose monitoring devices. Responses have been received concerning those issues from the Scottish Government and the Cabinet Secretary for Health and Sport.

For consideration of the petition, the cabinet secretary is accompanied by Dr Catherine Calderwood, who is the chief medical officer, and Elizabeth Sadler, who is the deputy director for planning and quality. I welcome the cabinet secretary and the officials to the meeting, and I invite her to provide a brief opening statement of no more than five minutes, after which we will move to questions.

Jeane Freeman SNP The Cabinet Secretary for Health and Sport · Carrick, Cumnock and Doon Valley
link

Good morning. I am grateful to Dr Calderwood for attending with me, given all the other pressures on her diary. I am grateful, too, to the committee for inviting me to give evidence on the petition.

As you will be aware from my letter of 8 August, the Scottish health technologies group published its advice statement on the flash glucose monitoring device FreeStyle Libre on 13 July 2018. My letter stated that the national health service boards that had not yet included FreeStyle Libre in their local formularies were considering how to implement the advice to best effect. To update the committee, all NHS boards in Scotland have included FreeStyle Libre in their local formularies and are making it available on prescription. I expect all boards to make FreeStyle Libre available to patients in line with clinical guidelines and in a phased and controlled manner to ensure that appropriate education is delivered prior to initiation and in recognition of the challenges for the manufacturer in matching demand. That move will benefit many individuals across Scotland, and I hope that it will reassure the committee that the spirit of the petitioner’s concerns in relation to FreeStyle Libre has now been met.

At the committee’s meeting on 28 June last year, my officials clarified that FreeStyle Libre is not a continuous glucose monitor. As more clinical evidence becomes available, FreeStyle Libre is showing positive effects in improving quality of life by reducing the number of finger-prick tests that patients need to carry out to self-manage their diabetes. However, FreeStyle Libre is not suitable for some patients, particularly for those who have limited or no hypoglycaemic awareness. There is strong clinical evidence to demonstrate that CGMs have a positive impact for a small cohort of patients with frequent or severe hypoglycaemia and that they improve glycaemic control and reduce hypoglycaemic episodes and emergency hospital admissions. We will continue to provide NHS boards with additional funding specifically for continuous glucose monitors so that the boards will increase the number available to diabetes patients where that is clinically indicated.

As the committee will be aware, diabetes remains a clinical priority for the Scottish Government. I reassure members that I am committed to ensuring that our health service continues to deliver care and treatment of the highest quality.

I am of course happy to answer any questions that members may have.

Johann Lamont Lab The Convener · Glasgow
link

Thank you. Committee members will recognise that the statement is very positive about the petition. You indicated that there are issues around training and the time for this to work through the system. Do you have a sense, if not a target, about when people across Scotland who would benefit will be able to routinely access FreeStyle Libre?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I do not have a target time; I am sure that committee members will understand that. Dr Calderwood may want to say more on that. Clinical judgment is needed about the appropriateness of FreeStyle Libre for a particular patient, and then there needs to be a bit of initiation and education with that patient. That has to happen at the secondary care level, but once it has been undertaken the prescription will come from an individual’s primary care giver.

The introduction will be phased, and it will be led by the number of individuals for whom this would be appropriate and by doing the necessary two steps before we get into regular prescribing for an individual. I do not know how that may pan out.

Dr Catherine Calderwood Scottish Government
link

We know that some of our health boards have come on stream very recently with availability of FreeStyle Libre. For a group of patients, the device will very obviously be the best choice and they may have been looking forward to the opportunity to use it. There will be a period of training for patients and their family members, who will need to attend and ensure that they are able to use the device. Once that has been undertaken, the prescription can go ahead. There is then a group of patients for whom there might be some additional work on whether it might be the right thing for them, and they might need a longer time until they move forward to using FreeStyle Libre.

The device is now available across Scotland in all our health boards and there will be clinical differences in the length of time for people to change over. It is not for everybody, but there is now no impediment to its use by those patients for whom it is the right way to monitor their glucose levels.

Angus MacDonald SNP Falkirk East
link

Good morning, cabinet secretary. I welcome the announcement, having been approached by a number of constituents about FreeStyle Libre. On our committee visit to Dumfries and Galloway some time ago, its benefits were brought to our attention.

You mentioned the clinical guidelines. The committee has previously heard evidence that the SIGN guidelines for type 1 diabetes management are out of date, because they have not kept up to date with technology. The committee understands that the guidelines will be withdrawn in 2020, rather than reviewed or updated. We are keen to hear your response on that point.

Evidence received by the committee has confirmed that proposals are in the pipeline to begin to update guidelines for type 2 diabetes this year. Why are there no similar plans or proposals to update the SIGN guidance for the management of type 1 diabetes?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

As you indicated, the technology is moving so fast that by the time the guidelines are updated, they are potentially out of date. What is being looked at is more rapid technical assessment, such as for glycaemic control in type 2. Professor Jason Leitch offered an explanation about that in his letter to the committee. What needs to be looked at is the system that would keep pace with technology while still offering the right guidance to clinicians. Dr Calderwood would like to add to that.

Dr Calderwood
link

The SIGN guidelines committee has changed its approach, and it is not specific to this particular diabetes guideline. The SIGN guidelines were being updated for everything every three years. Sometimes there was no change because there had been no more research, but sometimes there had been so much change that the guidelines were out of date.

The guidelines committee has therefore undertaken a complete change in the way that it will do the guidelines. The older guidelines will be retired and there has been a call for much more focused guidelines, rather than something that would take years to produce. With the new technology, we would be looking for the Scottish diabetes group to make a proposal to SIGN that has a very narrow focus. The new SIGN procedures mean that the proposal would be turned round very rapidly. SIGN might request a Scottish health technologies group assessment of the technology and then SIGN would look to quickly produce guidelines that are clinically relevant at that time.

In this new world in which we have FreeStyle Libre, it is for the Scottish diabetes group to make proposals to SIGN. SIGN has said that it will take on X pieces of work per year, which will be produced much more rapidly and which, I would argue in agreement with SIGN, will be much more clinically relevant than something that takes three or four years to produce.

Johann Lamont Lab The Convener · Glasgow
link

That point would apply to anything to do with modern technologies. Presumably, modern technology now applies across the medical landscape. Are you saying that, in the medium term, the SIGN guidelines will not be relevant?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No. I do not think that that is what Dr Calderwood or the guidelines committee is saying. This does not apply to everything, but there are areas in which technology is very relevant and it is moving quickly. The guidelines committee has therefore recognised that and has said that it needs to alter the way in which it undertakes its work, so that it can keep pace with that technology. In the past, taking two or three years to update guidelines was adequate but, in some instances, that is now too long. The guidelines would end up being out of date and would, in effect, be a significant waste of effort. Where it is appropriate, the guidelines committee will undertake a much more focused piece of work that tries to keep pace with the speed of technological developments in medicine and is clinically relevant, and which produces guidelines that add value for the clinicians in respect of the decisions that they have to take.

Johann Lamont Lab The Convener · Glasgow
link

In the meantime, there will be no SIGN guidelines for type 1 diabetes. How is a decision made about which areas across the board are subject to fast technology, and which areas are not? Presumably, there is a rational way of doing so. Obviously, the petitioner felt the need to lodge a petition in order to get health boards to catch up with technology. What reassurance can people be given that there is a rational process when such decisions are made?

Dr Calderwood
link

The original SIGN guidelines that we are talking about were written in 2010, so we are looking at something that needed to move on. As I described, we would expect the Scottish diabetes group to feed into SIGN. In the meantime, because we have the new technology, we will work with health boards, through the Scottish diabetes group, to make sure that, when patients should receive the technology, they have access to it. We will also monitor the use and uptake of the technology and whether there are any problems.

In respect of the prioritisation that SIGN is looking at, it has a workstream over a number of years but I could not tell you exactly what pieces of work are coming forward, or in what order. However, in Scotland, the idea is that we do not rely on guidance that is years out of date and that we do not have a situation in which the new research that is behind the guidance is not looked at. In common with the way in which guidelines are produced across the rest of the UK, that is a much more rapid process. The Scottish diabetes group is key in that.

09:15

Johann Lamont Lab The Convener · Glasgow
link

That does not necessarily address my point of concern, which is whether, across the board, we will have SIGN guidelines and whether they matter any more. What happens in other parts of the system? I apologise for digressing a wee bit. On the diabetes issues, there is another means by which folk are guaranteed that modern technology is being recognised and their access to the appropriate support is available. Perhaps we can come back to that digression.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

It is an important digression. If it would be helpful, we will pull together the information on how the guidelines committee is going about its work, and send it to the committee in direct response to the issues that you raise, convener.

However, for the record, it is important to be clear that neither SIGN nor the committee has said that SIGN guidelines are no longer relevant. The guidelines continue to be relevant, but the guidelines committee has looked to change and improve the way in which it goes about producing them, in order to match the pace at which things are moving forward.

We will pull something together on that and ensure that it is provided to the committee.

Johann Lamont Lab The Convener · Glasgow
link

That would be helpful, thank you. If someone with type 1 diabetes is looking at it from the outside and the guidelines are no longer available, they might think that their issues are being deprioritised.

Brian Whittle Con South Scotland
link

We recognise that, since the petition was lodged, there has been advancement in CGM and knowledge has been brought to the fore about what it can do for those who have type 1 and maybe even type 2 diabetes. In July 2018, the Scottish health technologies group published an advance statement on FreeStyle Libre flash glucose monitoring, recommending its use among adults who manage their condition with multiple daily insulin injections or insulin pump therapy, and the group concluded that it is good value for money.

Based on those findings, what is the cabinet secretary’s view as to the current level of Scottish Government funding that is available to health boards for the technology?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

The funding that is available to health boards is adequate for the demand that they have. As they shift to FreeStyle Libre where that is clinically appropriate, they will have resources from other things, such as finger-prick testing kits, that they will no longer need to use for certain individuals. They will be able to manage their resource by balancing what has been available up to now and the introduction of the new technology.

As I said in my statement, the Government has also provided additional funds, and we will continue to provide those.

Brian Whittle Con South Scotland
link

The public will be looking for consistency of application and an understanding of how we will reach that. I heard this morning that, in the Highlands, only four units are available and they are being given out to and being used by the youngest patients. That seems to go against what the Scottish health technologies group recommends. How can we reach a point where those who suffer from type 1 diabetes understand their position in relation to accessing the technology? There does not seem to be consistent application across all health boards.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I will ask Ms Sadler to respond to some of what you have said. However, I note that NHS Highland was the last board to come on stream, so it is later than other boards in going through the phased introduction that Dr Calderwood explained. Some work needs to be done to ensure that NHS Highland catches up in relation to the availability of the technology to patients for whom it is appropriate.

Ms Sadler may want to give some additional information on that.

Elizabeth Sadler Scottish Government
link

FreeStyle Libre and continuous glucose monitoring are two separate tools, but they produce similar things. FreeStyle Libre is now available on prescription across Scotland, with NHS Highland coming on board for that earlier this week. Whether FreeStyle Libre is a suitable technology for an individual is a clinical decision that will be taken by the individual and the clinician.

A continuous glucose monitor is a more invasive device—a person wears it and it goes into their body. A CGM is particularly suitable for people who have very poor glycaemic control and, in particular, people who have no awareness that they are about to have a hypo or a hypo episode, where it happens very suddenly. A CGM alerts the person that that is about to happen.

Over the past few years, the Scottish Government has provided additional funding of £2 million a year to support boards to increase the number of insulin pumps and CGMs, and that money is allocated on the basis of need and clinical decision making. According to the numbers that I have, nine over-18s in Highland have CGMs. I do not have a number for under-18s. Continuous glucose monitoring is being rolled out in conjunction with individuals and their clinicians. Some people are now choosing to have FreeStyle Libre rather than a pump because FreeStyle Libre is a less invasive procedure and it helps them to understand what is happening with their sugar controls.

Brian Whittle Con South Scotland
link

Presumably, given that health boards are not all adopting the technologies at the same time, health boards will be able to share what they have learned from early adoption.

Elizabeth Sadler Scottish Government
link

Absolutely. We understand that about 250 people across Scotland have continuous glucose monitors, and that number will increase over time. We think that we are reaching roughly 50 per cent of the people who would potentially benefit from a monitor. Some people who would benefit from a monitor may decide, in conjunction with their clinician, that they do not want one. We are making good progress, though, and we are committed to giving more money in 2019-20. We have just written to the boards to ask them about the progress that they have made in 2018-19, and we will then take decisions on the allocation of funding for next year.

Johann Lamont Lab The Convener · Glasgow
link

That is funding from April this year.

Elizabeth Sadler Scottish Government
link

Yes—for continuous glucose monitors and insulin pumps. FreeStyle Libre will be distributed by boards via prescription.

Johann Lamont Lab The Convener · Glasgow
link

We do not yet know what the allocation will be for decisions in April.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

We do not, but the funding is in the draft budget. Boards will tell us what their particular needs are and we will meet those needs by allocating that funding to the boards. It may vary depending on where boards have got to with provision in the current financial year and what more they need to do in the next financial year.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

It is not a bid; boards simply have to advise us of their need, show us evidence of their progress so far and tell us whether their need for the coming year looks like X or Y. We will then allocate funds from the pot that is already in the draft budget.

Maurice Corry Con West Scotland
link

We are hearing good news this morning. However, the Scottish health technologies group advises that further research is needed into the long-term use of CGM and its use with children and young people. Bearing in mind what the cabinet secretary said about how quickly the technology is moving, how will the Scottish Government respond to those findings and how does it intend to explore the issue further?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Mr Corry and I have corresponded on the issue in relation to a constituent case. I hope that what we have said this morning is helpful.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I ask Dr Calderwood to pick up on the point about research.

Dr Calderwood
link

We must try to ensure that all patients who would benefit from the new technologies get them. There is caution at first, which is why there are some restrictions. At the moment, FreeStyle Libre is recommended for people who are over 18 but not for pregnant women or people who are on dialysis, for example. However, we know that it would be the right thing to use for many people who are under 18.

The chief scientist office in the Scottish Government is under my jurisdiction. We are the envy of the rest of the United Kingdom for our ability to turn grant applications around and have funding available. We have a 30-day turnaround from submission to a decision on whether money will be given. If we have a particular interest in something—having whole-country coverage on this matter is new for Scotland—such a study is absolutely the right thing to propose.

Anyone can come forward, but we will approach the Scottish diabetes group, which has contacts with our researchers across Scotland and beyond, and people with an interest, such as Dr Brian Kennon, who is my specialty adviser on diabetes and has been to speak to the committee previously. We will introduce proposals so that research takes place as the coverage comes on board, with a view to spreading the availability of FreeStyle Libre to other patient groups if that is thought to be appropriate.

Maurice Corry Con West Scotland
link

Are you finding the results of the research useful in giving you leads and steers in how we deal with younger people with diabetes?

Dr Calderwood
link

Not many, if any, younger people are using FreeStyle Libre, because at the moment it is not recommended. It would be provided on an individual basis on the advice of a clinician who knows the young person very well. We need to look at its use on a case-by-case basis. However, as the technology is spread not only in Scotland but across the UK and beyond, numbers will come forward, and when we begin to have an evidence base that allows us to say that the technology is safe and effective to use with other groups of people, we will, of course, use it.

Maurice Corry Con West Scotland
link

Has the cabinet secretary built funding for such projects into her draft budget proposal?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

The chief scientist office has an allocation in the draft budget, and it is for that office to determine how it uses that allocation based on the research proposals that come forward. Quite rightly, such decisions will be made by people with scientific and medical expertise and not by people such as me. I will ensure that there is the appropriate allocation for the health portfolio in the overall draft budget to allow the chief scientist office to undertake the work. The office will then deal with its allocation according to its assessment of the various research proposals that come forward.

If I am correct, we are saying that use of FreeStyle Libre for under-18-year-olds is possible but it is decided on a case-by-case basis by clinicians based on their knowledge and understanding of and relationship with the individual, as Dr Calderwood said. In a way, the approach is not so different from the peer-approved clinical system approach to drug prescribing. Parallel to that, the Scottish diabetes group and the chief scientist office will consider research proposals that look to build on the evidence globally. We will look at the research base on which a decision to widen access to include under-18-year-olds might be taken.

David Torrance SNP Kirkcaldy
link

NHS boards have been asked to accurately record the introduction of all diabetes devices in the Scottish care information diabetes collaboration system. Can you confirm that the data is being recorded by all NHS boards? Are there any potential challenges for NHS boards in doing that?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I am not aware of any potential challenges for NHS boards; none has been raised with me. I understand that the boards are undertaking that work. If the committee would find it helpful, I would be happy for us to have a quick look round all the boards and get them to advise us as to where they are with that piece of work, so that the committee has that additional assurance.

Johann Lamont Lab The Convener · Glasgow
link

You said that you will deliver the devices. May I ask about costs? There was an issue to do with health boards being given an allocation but no funding for the associated VAT costs. We had an explanation about average prices and all that stuff, which—to be frank—was less than compelling. Can we get a commitment or a recognition that if you say, “We will deliver X number of devices”, you must will the means for that to happen, and that the issue to do with VAT will be addressed?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

You have that commitment from me. I see no point in embracing improved technologies where they are clinically appropriate but not making sure that, as far as we can, we allocate the resources to enable the improved technologies to be delivered to patients for whom they are appropriate.

Professor Leitch responded on the VAT issue in his letter, to which you referred. I have nothing to add to what he said about how the matter is approached. I assure the committee that boards are never slow in coming to me if they feel that they have not been given the adequate resource for a specific piece of work. If that happens as we progress through this work, we will look at the issue, as we always do.

Johann Lamont Lab The Convener · Glasgow
link

Do you accept the general principle that the cost of something includes what it will cost a health board to get it so, if you are not funding the VAT element, you are reducing the number?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No. I do not accept that, because, as we tried to explain earlier, boards have an overall allocation for prescribing and, as more and more individuals switch from, for example, finger-prick test kits to FreeStyle Libre, there will be a shift in how the resource is used, away from one and towards the other. I am happy to offer further written explanation of that, but our view is that, overall, that will enable boards to continue to manage the resource within the allocations that they have in the draft budget.

As boards go through the next financial year—if we assume that the draft budget will become the budget and the allocation will therefore remain as is planned—if they think that they are having difficulties meeting all the demands within their overall prescribing budgets, they will raise that directly with us, and we will look with them at what more can be done to assist them.

Emma Harper SNP South Scotland
link

I thank the committee for keeping me up to date on the petition. I declare an interest as a co-convener of the cross-party group on diabetes. I am also a type 1 diabetes pump user and a FreeStyle Libre user.

I clarify that routine finger-prick testing is still required when people use FreeStyle Libre and that there can be variability in the results because FreeStyle Libre uses interstitial glucose monitoring and not blood glucose monitoring. I wanted to clarify that finger-stick readings are still required to make sure that there is accuracy.

The use of interstitial glucose monitoring raises issues to do with assessing competence to drive. What work has been done with the Driver and Vehicle Licensing Agency on accepting FreeStyle Libre or continuous glucose monitoring, given that they involve interstitial testing? I think that, currently, blood glucose testing is required.

My other point is about children. The cabinet secretary said that children with type 1 diabetes who might be unaware of hypo and have seizure activity at night might benefit from FreeStyle Libre but they would work with their GP or specialist doctor on that, and a person-centred approach will be taken for kids. That point has been raised with me at the cross-party group as well as by constituents.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I ask Dr Calderwood to respond on children.

Dr Calderwood
link

You are absolutely right. It is about the individual. As you will be aware from the cross-party group, continuous glucose monitoring might be more appropriate than FreeStyle Libre for a child. At the moment, as with many new technologies and medications, the initial body of evidence is from adults. Because of individuals, we then creep, if you like, into expanding the indications. The important point is that those individuals are well known to their clinicians and their conditions are well known. The risks and benefits of any new treatment that does not have a body of evidence for an age group need to be considered so that the safety aspects are covered.

We know that continuous glucose monitoring, the flash glucose monitoring that FreeStyle Libre affords and insulin pumps are of great benefit to children for all the reasons that you will know. At the moment, we do not have the numbers to be able to point to big studies that say that this is the right thing to do, but that will come in time in Scotland and we can learn from the literature across the world.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

The DVLA requires sufficient evidence that glucose levels are sufficiently controlled, and it requires that evidence at the United Kingdom level. We are at a relatively early stage of being able to produce that evidence for the DVLA but, as it becomes available, it will be submitted and the DVLA will be asked to consider its approach in the light of that.

Emma Harper SNP South Scotland
link

Currently, people need to provide evidence of adequate blood glucose management using finger-stick devices because we are not yet at a point at which the DVLA will accept FreeStyle Libre or CGM results.

Brian Whittle Con South Scotland
link

I should have declared that I am also a co-convener of the cross-party group on diabetes. I apologise for not doing that earlier.

We heard in evidence that a compelling argument for the technology is that it has potential to help children with their sleep patterns because they would not have to be woken up to do finger-prick testing. That has been raised time and again in the cross-party group as an area of concern—and hope, I think—for a lot of people who have children with the condition.

Has any work been done on potential long-term savings to the budget from the introduction of the technology? I am asking about not just savings from not using the current kit, but longer-term savings from our being able to prevent those with the condition from sliding into the need for other, more costly treatments. That is where we want to be with the preventative health agenda. Has there been any long-term consideration of the budget?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

That is an important point, Mr Whittle, and I appreciate your asking about it. Where we can access the resources of economic analysts, I am keen that, in a number of areas across our work, we look to begin to develop that cost benefit approach and link it to the preventative agenda. I think that the preventative agenda needs a reinforcement of that type. I am sure that all of us in this room understand the importance of preventative work, but elsewhere it can feel like something that is nice to have if we can manage it and people can think, “Let’s just deal with what’s immediately in front of us.” There needs to be a stronger base, if you like, for the case.

I have begun some discussions about where we might look to initiate and have that work, which will not necessarily always be from inside the Scottish Government. A number of our major academic institutions have a keen interest in health areas and a lot of expertise in doing that economic analysis, and we are considering how we might identify the areas where we want some joint work to be done to move that forward. As we progress those discussions, I will be happy to ensure that certainly Mr Whittle, but also the committee more widely if members are interested, is informed of how we are doing.

Johann Lamont Lab The Convener · Glasgow
link

I call Emma Harper. Be brief, please.

Emma Harper SNP South Scotland
link

I will be brief. At the cross-party group on diabetes, we heard from a gentleman who had lost seven stone in weight with FreeStyle Libre, which he had self-funded through social prescribing, family support and so on, and he has now reached the point where he takes no medication for his type 2 diabetes. The likes of FreeStyle Libre can have an application if people so choose, and we would encourage those people to look at different approaches such as social prescribing and family support. Is any research being done on this type of monitoring for those with type 2?

Dr Calderwood
link

Because the technology has been introduced in the first instance for people with type 1 diabetes, the numbers are just not there for those with type 2. I suspect that people like the gentleman to whom you referred are dotted around the United Kingdom, but the difficulty is getting the numbers to do statistically effective research.

However, I absolutely agree that using all sorts of different methods, as that gentleman has done, is the right approach. It will probably take quite some time before there is enough interest in researching this particular area, but we are starting with something that shows a lot of promise and which will bring us benefits, including the economic benefits that Mr Whittle has referred to. Inevitably, given the numbers of people with type 2 diabetes, the use of these technologies will spread as we get more information about the safety aspects and the benefits.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Ms Sadler can give you additional information about our overall investment in work to help people with their diet and nutrition.

Elizabeth Sadler Scottish Government
link

We will be investing around £42 million over the next five years to support the implementation of the type 2 diabetes prevention framework that we published last year. It is aimed at supporting people who have been recently diagnosed with or who are at high risk of type 2 diabetes in losing weight or changing to a healthier lifestyle, to see whether it is possible to reverse their diabetes or to reduce the rate at which the complications from their diabetes arise, which will obviously keep people healthier for longer.

Johann Lamont Lab The Convener · Glasgow
link

I want to ask a final brief question. The committee understands that NHS boards are being supported by a part-time continuous glucose monitoring diabetes specialist nurse. Can you confirm the remit and scope of that role and describe how its impact is being measured? Would you like to see it developed?

Elizabeth Sadler Scottish Government
link

The purpose of the role is to work with boards and provide support to teams in identifying the most appropriate people with regard to the technologies, and supporting the learning and education that those people will need before they can be prescribed a pump, CGM or FreeStyle Libre. It is a relatively new post, and at the moment, it will last three years. I am not aware of our having done any formal evaluation of it, but I know that it is proving very helpful in supporting boards and that the boards have welcomed the additional help and support that they are getting from the specialist nurse.

Johann Lamont Lab The Convener · Glasgow
link

Given the quite significant statement that has been made about access to the technology, the recognition that it needs to be rolled out and, indeed, the commitment that the Scottish Government has made in that respect, do you think that a part-time post for the whole of Scotland is sufficient to do the groundwork to liberate access to the technology?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Of course, boards already have clinically skilled and professionally expert teams working in this area of diabetes, and the nurse is, in effect, providing additional support in that respect.

We must not allow anyone to think that all that is happening is that a part-time resource is being provided. I cannot recall which member asked about the sharing of good practice—it might have been Mr Whittle. The role also entails involvement in the sharing of good practice between those boards that brought FreeStyle Libre into their local formularies earlier than others, to help other boards to benefit from that early learning.

At this point, we have had no indication from boards that they require a resource in addition to that three-year commitment. There has been a lot of feedback from boards that the role is proving very helpful to them.

09:45

Johann Lamont Lab The Convener · Glasgow
link

I presume that, in the normal run of things, the Government would look at whether that was the best use of that resource, given the cabinet secretary’s suggestion that such work is being done anyway, and at what added value the specialist nurse provides.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No—I apologise if what I said led to that misunderstanding. I did not say that such work is being done anyway. I said that individual boards already have groups of people who are clinically and professionally expert in the area of diabetes and in working with patients with type 1 diabetes and those with type 2 diabetes. The specialist nurse is an additional resource for helping the boards with the new technologies.

As Ms Sadler said, it is early days in the three-year timespan. Evaluation work will be done on whether more is needed beyond the three years, but we are talking about a resource to help boards with the new technologies that is additional to the board-based expertise that they already have.

Johann Lamont Lab The Convener · Glasgow
link

Thank you for that useful clarification. I think that we have finished our questions. Thank you very much for a very positive contribution, cabinet secretary.

In terms of what the petitioner is looking for, we might want to reflect on the evidence. We could give the petitioner and others the opportunity to respond to what they have heard, after which we can draw a final conclusion. Would that be fair?

Members indicated agreement.

Johann Lamont Lab The Convener · Glasgow
link

Therefore, we will reflect on the very positive evidence that we have heard today and those with an interest in the petition will be able to make further submissions. At that point, we can come to conclusions on the petition. I thank the cabinet secretary for answering our questions.

  1. 09:00 Continued Petitions Petitions · 1
  2. 09:15 Continued Petitions Petitions · 68
  3. 09:45 Continued Petitions Petitions · 84
  4. 10:15 Continued Petitions Petitions · 52

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.